Alnylam to Webcast Conference Call Discussing First Quarter 2019 Financial Results
April 23 2019 - 4:00PM
Business Wire
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading
RNAi therapeutics company, announced today that it will report
financial results for the first quarter ending March 31, 2019 on
Wednesday, May 1, 2019, before the U.S. financial markets open.
Management will provide an update on the Company and discuss
first quarter 2019 results as well as expectations for the future
via conference call on Wednesday, May 1, 2019 at 8:30 am ET. To
access the call, please dial 800-289-0438 (domestic) or
323-794-2423 (international) five minutes prior to the start time
and refer to conference ID 4935120. A replay of the call will be
available beginning at 11:30 am ET on the day of the call. To
access the replay, please dial 888-203-1112 (domestic) or
719-457-0820 (international) and refer to conference ID
4935120.
A live audio webcast of the call will be available on the
Investors section of the Company’s website, www.alnylam.com. An
archived webcast will be available on the Alnylam website
approximately two hours after the event.
About Alnylam PharmaceuticalsAlnylam (Nasdaq: ALNY) is
leading the translation of RNA interference (RNAi) into a whole new
class of innovative medicines with the potential to transform the
lives of people afflicted with rare genetic, cardio-metabolic,
hepatic infectious, and central nervous system (CNS)/ocular
diseases. Based on Nobel Prize-winning science, RNAi therapeutics
represent a powerful, clinically validated approach for the
treatment of a wide range of severe and debilitating diseases.
Founded in 2002, Alnylam is delivering on a bold vision to turn
scientific possibility into reality, with a robust discovery
platform. Alnylam’s first U.S. FDA-approved RNAi therapeutic is
ONPATTRO® (patisiran) lipid complex injection available in the U.S.
for the treatment of the polyneuropathy of hereditary
transthyretin-mediated (hATTR) amyloidosis in adults. In the EU,
ONPATTRO is approved for the treatment of hATTR amyloidosis in
adults with stage 1 or stage 2 polyneuropathy. Alnylam has a deep
pipeline of investigational medicines, including five product
candidates that are in late-stage development. Looking forward,
Alnylam will continue to execute on its “Alnylam 2020” strategy of
building a multi-product, commercial-stage biopharmaceutical
company with a sustainable pipeline of RNAi-based medicines to
address the needs of patients who have limited or inadequate
treatment options. Alnylam employs over 1,000 people worldwide and
is headquartered in Cambridge, MA. For more information about our
people, science and pipeline, please visit www.alnylam.com and
engage with us on Twitter at @Alnylam or on LinkedIn.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190423005637/en/
Alnylam Pharmaceuticals, Inc.Christine Regan
Lindenboom(Investors and Media)617-682-4340
Josh Brodsky(Investors)617-551-8276
Alnylam Pharmaceuticals (NASDAQ:ALNY)
Historical Stock Chart
From Aug 2024 to Sep 2024
Alnylam Pharmaceuticals (NASDAQ:ALNY)
Historical Stock Chart
From Sep 2023 to Sep 2024